Skip to content

A medical records based analysis of prognosis of breast cancer patients with low expression of ER and PR by platinum based chemotherapy

Clinical analysis of prognosis of breast cancer patients with low expression of ER and PR by platinum based chemotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200057367
Enrollment
Unknown
Registered
2022-03-09
Start date
2022-03-09
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

test group:DDEC-TP scheme auxiliary chemotherapy

Sponsors

The third Department of breast surgery, Yunnan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The patient is female, aged = 18 years; 2. ECOG score 0-1; 3. It is confirmed by pathology as unilateral or bilateral primary invasive carcinoma of the breast; 4. Immunohistochemistry (IHC) showed that the expression of ER or/and PR was low (1-20%) and HER-2 was negative; 5. According to the current AJCC breast cancer staging standards, the researchers have evaluated the patients as I-III based on radiology and/or clinical evaluation; 6. The patient has undergone modified radical mastectomy or breast conserving radical mastectomy for breast cancer. After surgery, ddEC-TP scheme was used as adjuvant chemotherapy, and chemotherapy has ended.

Exclusion criteria

Exclusion criteria: 1. Distant metastasis of breast cancer at any location (stage IV); 2. After mastectomy or minimally invasive rotary resection; 3. Have received endocrine therapy or castration therapy in the past; 4. Incomplete baseline information or immunohistochemical results; 5. Have a history of other malignant tumors; 6. Patients with severe cardiac insufficiency, liver and kidney insufficiency, active mental system diseases (schizophrenia, severe depression, bipolar disorder, etc.); 7. Not willing to sign the informed consent form; 8. Persons without full civil capacity; 9. In the opinion of the researchers, other conditions make them unsuitable for this study.

Design outcomes

Primary

MeasureTime frame
Disease-free survival;

Countries

China

Contacts

Public ContactWenlin Chen

The third Department of breast surgery, Yunnan Cancer Hospital

1205756171@qq.com+86 18287107794

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026